Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc (LIFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Atyr Pharma: Q4 Earnings Snapshot

Atyr Pharma: Q4 Earnings Snapshot

LIFE : 1.6000 (-1.23%)
Atyr Pharma: Q3 Earnings Snapshot

Atyr Pharma: Q3 Earnings Snapshot

LIFE : 1.6000 (-1.23%)
Atyr Pharma: Q2 Earnings Snapshot

Atyr Pharma: Q2 Earnings Snapshot

LIFE : 1.6000 (-1.23%)
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 1.6000 (-1.23%)
AADI : 1.8400 (+2.22%)
Atyr Pharma: Q1 Earnings Snapshot

Atyr Pharma: Q1 Earnings Snapshot

LIFE : 1.6000 (-1.23%)
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 1.6000 (-1.23%)
TSVT : 4.52 (-2.59%)
Atyr Pharma: Q4 Earnings Snapshot

Atyr Pharma: Q4 Earnings Snapshot

LIFE : 1.6000 (-1.23%)
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LIFE : 1.6000 (-1.23%)
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 1.6000 (-1.23%)
ROIV : 10.46 (+0.97%)
Atyr Pharma: Q3 Earnings Snapshot

Atyr Pharma: Q3 Earnings Snapshot

LIFE : 1.6000 (-1.23%)

Barchart Exclusives

Dividend Newcomers: Discover 3 Companies Starting To Share the Wealth
Discover the potential of newly initiated dividends—start building your wealth with tomorrow's top dividend payers today! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar